In a multicenter retrospective study (30), a total of 21 advanced NSCLC patients received camrelizumab combined with rh-endostatin and chemotherapy (76% for adenocarcinoma and 19% for squamous cell carcinoma), ORR and DCR were 71% and 100%, 1 patient received CR, and 11 patients (52%) were undergoing treatment, mPFS was not achieved, and the safety is good. Here, COL18A1 is linked to adenocarcinoma.